Title:
TREATMENT OF HEPATITIS DELTA VIRUS INFECTION
Document Type and Number:
WIPO Patent Application WO/2016/090107
Kind Code:
A3
Abstract:
Tipifarnib or a tipifarnib derivative is used to treat HDV infection as a monotherapy or in combination with an interferon and/or boosting agent such as a CYP3A4 inhibitor such as ritonavir and cobicistal. This invention arises in part out of the surprising discoveries that not all prenyltransferase inhibitors are efficacious in treating HDV infection and that tipifarnib (Rl 15777) and tipifarnib derivatives such as R208176_can be administered at a dose efficacious in humans. This invention accordingly provides a method of inhibiting HDV replication in a human subject known to be co-infected with HBV and HDV by administering a therapeutically effective dose of tipifamib, R208176 and other therapeutically effective tipifarnib derivatives and pharmaceutically acceptable salts and other forms.
Inventors:
CORY DAVID (US)
CHOONG INGRID (US)
GLENN JEFFREY S (US)
CHOONG INGRID (US)
GLENN JEFFREY S (US)
Application Number:
PCT/US2015/063674
Publication Date:
October 27, 2016
Filing Date:
December 03, 2015
Export Citation:
Assignee:
EIGER BIOPHARMACEUTICALS INC (US)
International Classes:
A61P31/12
Domestic Patent References:
| WO2011088126A2 | 2011-07-21 |
Foreign References:
| US20030114471A1 | 2003-06-19 | |||
| US20130102526A1 | 2013-04-25 | |||
| US7511027B2 | 2009-03-31 |
Other References:
BLANCHET ET AL.: "Use of FDA approved therapeutics with hNTCP metabolic inhibitory properties to impair the HDV lifecycle", ANTIVIRAL RES., vol. 106, 6 April 2014 (2014-04-06), pages 111 - 115, XP028653123
Attorney, Agent or Firm:
APPLE, Randolph T. (Two Embarcadero CenterEighth Floo, San Francisco California, US)
Download PDF: